Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
iwMyeloma 2024
The 17th International Workshop on Myeloma (iwMyeloma)
12–14 April 2024 | Miami, FL
Expert-led presentations & roundtable discussions from iwMyeloma 2024, covering the latest advancements in multiple myeloma.
Explore roundtable discussions from iwMyeloma 2024
View all videos
Genomics 2024
An all-genetic classifier of MM and individualized prognostic scores
Francesco Maura Memorial Sloan Kettering Cancer Center, New York, NY, United States
The ncGenome in multiple myeloma
Patrick Blaney NYU Langone Health, New York City, NY, United States
Tumor suppressor gene inactivation
Bachisio Ziccheddu Sylvester Comprehensive Cancer Center, Miami, FL, United States
Membrane markers as targets in t(4:14)
Arun Wiita University of California San Francisco, San Francisco, CA, United States
Resistance mechanisms
Chr1q in the evolution to HR MM
Monika Chojnacka University of Miami, Miami, FL, United States
Mechanisms of resistance to bispecifics
Paola Neri University of Calgary, Calgary, Canada
Transcriptional resistance to IMiDs
Leif Bergsagel Mayo Clinic, Phoenix, AZ, United States
Genomic profiling of treated smoldering multiple myeloma
Benjamin Diamond Sylvester Comprehensive Cancer Center, Miami, FL, United States
Biological basis of therapy
Treatment of high-risk myeloma
Robert Orlowski The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Epigenetic & microenvironment drivers of disease progression
Felipe Prósper University of Navarra, Navarra, Spain
MMRF updates
MyDRUG trial – status and learnings
Noa Biran Hackensack Meridian School of Medicine, Edison, NJ, United States
CoMMpass at 13 – the gift that keeps giving
Lawrence Boise Emory Winship Cancer Institute, Atlanta, GA, United States
MMRF clinical and translational research strategy:
George Mulligan Multiple Myeloma Research Foundation, Boston, MA, United States
Clinical trial updates
Strategies for the clinical evaluation of bispecifics
Ola Landgren Sylvester Comprehensive Cancer Center, Miami, FL, United States
Isatuximab combinations for the treatment of MM
Thomas Martin University of California, San Francisco, CA, United States
Bisphosphonates – what comes next?
Suzanne Lentzsch Columbia University Medical Center, New York, NY, United States
Novel targets
CLR 131 (Iopofosine I-131) in R/R multiple myeloma
Sikander Ailawadhi Mayo Clinic, Jacksonville, FL, United States
Debates in myeloma
For bispecifics
Marc Raab Heidelberg Myeloma Center, Heidelberg, Germany
For long-duration therapy with bispecifics & for short-term
Ola Landgren Sylvester Comprehensive Cancer Center, Miami, FL, United States
T-cell engagers
Innovative CAR-T designs and targets
Hermann Einsele Würzburg University Hospital, Würzburg, Germany
ADC in the multiple myeloma context
Hans Lee The University of Texas MD Anderson Cancer Center, Houston, TX, United States
CAR-T developments
Yi Lin Mayo Clinic, Rochester, MN, United States
iwMyeloma 2024 is supported by:
Platinum Supporters
Gold Supporters
Silver Supporters
Bronze Supporters
